|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential blood count, CRP, neutrophil and monocyte-macrophage activation markers, cortisol and psychotic symptoms (Positive and Negative Syndrome Scale [PANSS]) were assessed in controls (n = 294) and acutely ill unmedicated FEP (n = 129) and Sz (n = 124) patients at baseline and after 6 weeks treatment.
|
31504969 |
2020 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP has been found to be elevated in patients with mood disorders (especially unipolar disorders (UD) and in schizophrenia (SZ)) but also to be lowered by antidepressants.
|
31676465 |
2020 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Levels of High Sensitivity C-reactive Protein in Drug-naÏve First-episode Psychosis and Acute Exacerbation of Schizophrenia.
|
30905124 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate the correlation between BMI and CRP while relating both variables to plasma lipids in patients with schizophrenia.
|
30315442 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia.
|
31118157 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia.
|
31571879 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also highlight the absent effects of genetic liability to schizophrenia on CRP levels.
|
31504541 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum high-sensitivity C-reactive protein levels are positively associated with cognitive impairments in patients with first-episode schizophrenia.
|
31450022 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, both BDNF [r = 0.12, confidence interval (CI) 0.04-0.19] and CRP (r = -0.13, CI 0.08-0.18) levels were very modestly but significantly related to cognitive functioning in schizophrenia (r = 0.12, CI 0.04-0.19).
|
31284882 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There was no significant relationship between the serum PGE2, 15d-PGJ and PPARγ levels and CRP levels.In this study, the evidence of systemic inflammatory conditions in patients with schizophrenia was found.
|
31590005 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].
|
31214940 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Schizophrenia is associated with aberrant blood cytokine and C-reactive protein (CRP) levels.
|
30967316 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Most consistent results indicate worse cognitive performance in schizophrenia patients with higher CRP levels.
|
28416092 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
No significant changes were found for CRP in schizophrenia compared with their matched controls.
|
29310912 |
2018 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inadvertently, studies of CRP among the Indian schizophrenia patients are very few.
|
29464976 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Findings reported elevated CRP levels in schizophrenia, mainly correlated with the severity of illness and during the recrudescent phase.
|
29357805 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The finding of our meta-analysis has identified significantly altered maternal CRP and cytokine concentrations in schizophrenia, strengthening evidence of maternal immune system dysregulation in neuropsychiatric disorders where inflammatory signals dominate.
|
30212728 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated CRP may be a biomarker of poor 1-year clinical course in patients with schizophrenia.
|
30273893 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we detected a robust increase of the levels of syncytin-1 and CRP in schizophrenia patients, and displayed a positive correlation and marked consistency between expressions of syncytin-1 and CRP in schizophrenia patients.
|
28928004 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In independent samples, we assessed the peripheral inflammation marker C-reactive protein (CRP) to determine the extent to which: (1) CRP was elevated and stable across admissions for acute psychosis, (2) cognition, daily function and symptom severity are characteristic of chronically ill patients with schizophrenia displaying elevated CRP, and (3) CRP levels predict cortical thickness.
|
30364161 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased CRP has also been associated with high nicotine dependence in SZ smokers and one study has suggested that increased CRP was associated with sedentary behavior.
|
30190688 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the association between CRP level and depressive symptoms has been poorly investigated in patients with schizophrenia.
|
28917193 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To estimate risk for Scz attributable to CRP and PGRS, serum from these participants was assayed for CRP levels using enzyme linked immunosorbent assays.
|
29306175 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with the levels in the schizophrenia group, the levels of CRP in the bipolar disorder and depression groups, the level of IFN-γ in the bipolar disorder group, and the levels of NGAL in the anxiety disorder and depression groups were significantly decreased (P < 0.05).
|
29028592 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Procalcitonin and C - reactive protein as peripheral inflammatory markers in antipsychotic drug-free schizophrenia patients.
|
29723719 |
2018 |